Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.

Handle F, Prekovic S, Helsen C, Van den Broeck T, Smeets E, Moris L, Eerlings R, Kharraz SE, Urbanucci A, Mills IG, Joniau S, Attard G, Claessens F.

Sci Rep. 2019 Sep 24;9(1):13786. doi: 10.1038/s41598-019-50220-1.

2.

The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA.

Mol Cancer Res. 2019 Aug 8. doi: 10.1158/1541-7786.MCR-18-0605. [Epub ahead of print]

PMID:
31395667
3.

High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.

Itkonen HM, Urbanucci A, Martin SE, Khan A, Mathelier A, Thiede B, Walker S, Mills IG.

Theranostics. 2019 Apr 12;9(8):2183-2197. doi: 10.7150/thno.30834. eCollection 2019.

4.

Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer.

Braadland PR, Urbanucci A.

Endocr Relat Cancer. 2019 Apr 1;26(4):R211-R235. doi: 10.1530/ERC-18-0579. Review.

PMID:
30844748
5.

Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer.

Braadland PR, Urbanucci A.

Endocr Relat Cancer. 2019 Feb 1. pii: ERC-18-0579.R1. doi: 10.1530/ERC-18-0579. [Epub ahead of print] Review.

PMID:
30780131
6.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
7.

The expression of AURKA is androgen regulated in castration-resistant prostate cancer.

Kivinummi K, Urbanucci A, Leinonen K, Tammela TLJ, Annala M, Isaacs WB, Bova GS, Nykter M, Visakorpi T.

Sci Rep. 2017 Dec 21;7(1):17978. doi: 10.1038/s41598-017-18210-3.

8.

Bromodomain-containing proteins in prostate cancer.

Urbanucci A, Mills IG.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):31-40. doi: 10.1016/j.mce.2017.06.007. Epub 2017 Jun 15. Review.

PMID:
28624514
9.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

10.

Lipid degradation promotes prostate cancer cell survival.

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG.

Oncotarget. 2017 Jun 13;8(24):38264-38275. doi: 10.18632/oncotarget.16123.

11.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

12.

Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.

Zuber V, Bettella F, Witoelar A; PRACTICAL Consortium; CRUK GWAS; BCAC Consortium; TRICL Consortium, Andreassen OA, Mills IG, Urbanucci A.

BMC Genomics. 2017 Mar 31;18(1):270. doi: 10.1186/s12864-017-3620-y.

13.

Cell cycle-coupled expansion of AR activity promotes cancer progression.

McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE.

Oncogene. 2017 Mar 23;36(12):1655-1668. doi: 10.1038/onc.2016.334. Epub 2016 Sep 26.

14.

CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions.

Fiorito E, Sharma Y, Gilfillan S, Wang S, Singh SK, Satheesh SV, Katika MR, Urbanucci A, Thiede B, Mills IG, Hurtado A.

Nucleic Acids Res. 2016 Dec 15;44(22):10588-10602. Epub 2016 Sep 15.

15.

Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells.

Tekpli X, Urbanucci A, Hashim A, Vågbø CB, Lyle R, Kringen MK, Staff AC, Dybedal I, Mills IG, Klungland A, Staerk J.

Epigenetics Chromatin. 2016 May 31;9:21. doi: 10.1186/s13072-016-0070-8. eCollection 2016.

16.

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V, Pimanda JE, Maitland NJ, Westermarck J, Visakorpi T.

Oncotarget. 2015 Aug 14;6(23):19661-70.

17.

Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.

Barfeld SJ, Fazli L, Persson M, Marjavaara L, Urbanucci A, Kaukoniemi KM, Rennie PS, Ceder Y, Chabes A, Visakorpi T, Mills IG.

Oncotarget. 2015 May 20;6(14):12587-602.

18.

Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.

Lund K, Dembinski JL, Solberg N, Urbanucci A, Mills IG, Krauss S.

PLoS One. 2015 Apr 10;10(4):e0123684. doi: 10.1371/journal.pone.0123684. eCollection 2015.

19.

Androgen-regulated metabolism and biosynthesis in prostate cancer.

Barfeld SJ, Itkonen HM, Urbanucci A, Mills IG.

Endocr Relat Cancer. 2014 Aug;21(4):T57-66. doi: 10.1530/ERC-13-0515. Epub 2014 Feb 4. Review.

PMID:
24497572
20.

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

Lehmusvaara S, Erkkilä T, Urbanucci A, Jalava S, Seppälä J, Kaipia A, Kujala P, Lähdesmäki H, Tammela TL, Visakorpi T.

Prostate. 2013 Jan;73(1):101-12. doi: 10.1002/pros.22545. Epub 2012 Jun 5.

PMID:
22674191
21.

Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T.

J Pathol. 2012 Jul;227(3):336-45. doi: 10.1002/path.4027. Epub 2012 May 8.

PMID:
22431170
22.

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.

Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T.

Oncogene. 2012 Oct 11;31(41):4460-71. doi: 10.1038/onc.2011.624. Epub 2012 Jan 23.

PMID:
22266859
23.

Androgen receptor (AR) aberrations in castration-resistant prostate cancer.

Waltering KK, Urbanucci A, Visakorpi T.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):38-43. doi: 10.1016/j.mce.2011.12.019. Epub 2012 Jan 8. Review.

PMID:
22245783
24.

Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure.

Urbanucci A, Marttila S, Jänne OA, Visakorpi T.

Prostate. 2012 Aug 1;72(11):1223-32. doi: 10.1002/pros.22473. Epub 2011 Dec 27.

PMID:
22212979
25.

Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.

Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lähdesmäki H, Jänne OA, Visakorpi T.

Oncogene. 2012 Apr 26;31(17):2153-63. doi: 10.1038/onc.2011.401. Epub 2011 Sep 12.

PMID:
21909140
26.

Androgen regulation of micro-RNAs in prostate cancer.

Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T.

Prostate. 2011 May;71(6):604-14. doi: 10.1002/pros.21276. Epub 2010 Oct 13.

PMID:
20945501
27.

Potential internalisation of caliciviruses in lettuce.

Urbanucci A, Myrmel M, Berg I, von Bonsdorff CH, Maunula L.

Int J Food Microbiol. 2009 Oct 31;135(2):175-8. doi: 10.1016/j.ijfoodmicro.2009.07.036. Epub 2009 Aug 6.

PMID:
19720414
28.

Androgen regulation of the androgen receptor coregulators.

Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T.

BMC Cancer. 2008 Aug 1;8:219. doi: 10.1186/1471-2407-8-219.

Supplemental Content

Loading ...
Support Center